
Fate Therapeutics (FATE) Stock Forecast & Price Target
Fate Therapeutics (FATE) Analyst Ratings
Bulls say
Fate Therapeutics Inc. is recognized as a leading developer of induced pluripotent stem cell (iPSC)-derived cancer therapeutics, particularly focusing on NK cell therapies that address challenges such as off-the-shelf availability and reduced manufacturing costs. Early clinical data presented at the recent American College of Rheumatology meeting highlighted the promising efficacy of its off-the-shelf CD19 CAR-T product candidate, FT819, in treating patients with systemic lupus erythematosus, showcasing significant improvements in key health scores without severe adverse effects. The company's strong pipeline and innovative technology position it favorably in the competitive landscape of cellular immunotherapies, contributing to a positive outlook on its stock performance.
Bears say
Fate Therapeutics Inc. faces significant risks that could negatively impact its stock, including the potential failure of its product FT819 to demonstrate meaningful clinical efficacy compared to existing CAR-T therapies and concerns regarding safety and immunogenicity. Furthermore, the company may encounter challenges related to partnerships and unfavorable reactions from regulatory agencies, which could hinder its development efforts. Additionally, medium-term dilution risk poses a financial threat, potentially affecting shareholder value and investor confidence.
This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Fate Therapeutics (FATE) Analyst Forecast & Price Prediction
Start investing in Fate Therapeutics (FATE)
Order type
Buy in
Order amount
Est. shares
0 shares